(Q35798789)

10 August 2017

1 reference

title

Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections (English)

1 reference

10 August 2017

Bong K Yoo

1

1 reference

10 August 2017

Darren M Triller

series ordinal

2

1 reference

10 August 2017

Chul-Soon Yong

series ordinal

3

1 reference

10 August 2017

Thomas P Lodise

series ordinal

4

1 reference

10 August 2017

language of work or name

English

0 references

publication date

8 June 2004

1 reference

Annals of Pharmacotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

38

1 reference

10 August 2017

issue

7-8

1 reference

10 August 2017

page(s)

1226-1235

1 reference

Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.

10 August 2017

cites work

1 reference

Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus

21 January 2018

1 reference

Mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from canine infections

21 January 2018

1 reference

21 January 2018

1 reference

Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity

21 January 2018

1 reference

Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro

21 January 2018

1 reference

Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones

21 January 2018

1 reference

Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae

21 January 2018

1 reference

Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae

21 January 2018

1 reference

Antipneumococcal activities of gemifloxacin compared to those of nine other agents

21 January 2018

1 reference

The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access?

21 January 2018

1 reference

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

21 January 2018

1 reference

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones

21 January 2018

1 reference

A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.

21 January 2018

1 reference

In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis

21 January 2018

1 reference

Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.

21 January 2018

1 reference

In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone

21 January 2018

1 reference

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

21 January 2018

1 reference

A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group

21 January 2018

1 reference

In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens

21 January 2018

1 reference

Comparative in vitro activity of gemifloxacin.

21 January 2018

1 reference

In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea

21 January 2018

1 reference

Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).

21 January 2018

1 reference

Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae

21 January 2018

1 reference

In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany

21 January 2018

1 reference

Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.

21 January 2018

1 reference

In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.

21 January 2018

1 reference

In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene

21 January 2018

1 reference

Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.

21 January 2018

1 reference

In vitro activities of gemifloxacin versus five quinolones and two macrolides against 271 Spanish isolates of Legionella pneumophila: influence of charcoal on susceptibility test results.

21 January 2018

1 reference

Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756

21 January 2018

1 reference

In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae

21 January 2018

1 reference

Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections

21 January 2018

1 reference

Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers

21 January 2018

1 reference

21 January 2018

1 reference

Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers

21 January 2018

1 reference

The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers.

21 January 2018

1 reference

The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers

21 January 2018

1 reference

Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical

21 January 2018

1 reference

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin

21 January 2018

1 reference

A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes

21 January 2018

1 reference

Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis

21 January 2018

1 reference

Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections

21 January 2018

1 reference

A critical review of the fluoroquinolones: focus on respiratory infections

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E003

1 reference

10 August 2017

1 reference